News Center

News Center

Home page

Blog Center

News Center

Viwit Pharmaceuticals' Sterile Production Facility Successfully Passes U.S. FDA Inspection

Viwit Pharmaceutical's Phenylephrine Hydrochloride Injection Officially Receives Official Approval by China NMPA

Viwit Pharmaceuticals’ Brimonidine tartrate and Timolol maleate eye drops receive Official Approval by China NMPA

Viwit's Nitroglycerin Sublingual Tablets Approved by FDA

Viwit Pharmaceuticals API Site Successfully Passed FDA cGMP On-site Audit with "No Action Indicated"

Viwit Pharmaceutical Co. Ltd. announces exclusive licensing and supply agreement for two Gadolinium based Magnetic Resonance Imaging (MRI) injectable contrast agents in the US.

Welcome participants in CPhI India 2018, booth number: 4.H15

Author：

Release Time：

2018-12-12

Welcome participants in CPhI India 2018, booth number: 4.H15

CPhI India 2018 will be held from December 12th to 14th, 2018 at the Expo Center in Delhi, India. Welcome to patronage of Viwit, booth number: 4.H15. If you want to make an appointment in advance, please send an email to service@viwit.com

Previous

CPhI India 2018, Booth No. 4.H15

Congratulations to Viwit Pharmaceutical Co., Ltd. for passing GMP certification of Health Canada

Next

VIWIT

Technical Support:China Enterprise Cross-border | SEO Tags

【Business License】

Search